Diabetes Patients Look Forward to Lower-Priced Insulin

Eli Lilly plans to introduce a lower-priced product in the United States.

Less than two weeks after the Senate Finance Committee investigated big pharma companies about drug pricing policies, Eli Lilly has announced plans to introduce a lower-priced product in the United States. In fact, the committee requested that Eli Lilly provide information about its insulin pricing before March 8. 

The discounted version of Lilly’s Humalog (insulin lispro injection 100 units/mL) will be called Insulin Lispro and will be available in vial and pen options at list prices 50% lower than the current Humalog prices ($137.35 for a single vial and $265.20 for a five-pack of KwikPens). The authorized generic product will be made available through the Lilly subsidiary ImClone Systems. 

Introducing an alternative insulin option allows Lilly to provide lower-priced insulin more quickly while providing payers time to renegotiate downstream contracts and adjust to new system economics, according to the company. Lilly also indicated that, after exploring the logistics and feasibility of an authorized generic, it began preparing manufacturing, labeling and shipping plans in 2018 for the possibility of introducing Insulin Lispro.

David Alvaro, Ph.D.

David is Scientific Editorial Director for That’s Nice and the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University and a Ph.D. in Genetics and Development from Columbia University.